AH Bio Fund II, L.P.

Reported to SECin USFilings at 1 company

No score on this page, by design. These filings come from the American register (SEC). We show them as facts, with what the share price did since each filing and since each trade; our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Everything we currently hold fits inside that, so nothing is being held back here today. Reading the whole list, and the full version of the page each row opens (that page itself opens free, with its first rows), is part of the subscription. So are this filer’s key figures and the price change beside each line, since the filing and since the trade. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Filings

Most recent filing first. Reported is the day the filing reached the regulator, usually a few days after the trade itself.

5
Reported insider transactions
CompanyTypeValueReportedCompanyValueTypeSharesReported
Scribe Therapeutics, Inc.—Conversionnothing paid4,131,344 sharesJul 29, 2026Scribe Therapeutics, Inc.nothing paidConversion · Jul 29Conversion4,131,344Jul 29, 2026
Scribe Therapeutics, Inc.—Conversionnothing paid12,150,003 sharesJul 29, 2026Scribe Therapeutics, Inc.nothing paidConversion · Jul 29Conversion12,150,003Jul 29, 2026
Scribe Therapeutics, Inc.—Open-market buy$4,999,995333,333 sharesJul 29, 2026Scribe Therapeutics, Inc.$4,999,995Buy · Jul 29Open-market buy333,333Jul 29, 2026
Scribe Therapeutics, Inc.—Conversion—697,650 sharesJul 29, 2026Scribe Therapeutics, Inc.—Conversion · Jul 29Conversion697,650Jul 29, 2026
Scribe Therapeutics, Inc.—Conversion—2,051,742 sharesJul 29, 2026Scribe Therapeutics, Inc.—Conversion · Jul 29Conversion2,051,742Jul 29, 2026